# Cholesterol Lowering Via Bempedoic Acid/Ezetimibe, an ACL-Inhibiting Regimen in Acute Coronary Syndrome Study

> **NCT05263778** · PHASE4 · UNKNOWN · sponsor: **Kaiser Permanente** · enrollment: 500 (estimated)

## Conditions studied

- Cardiovascular Diseases
- NSTEMI
- STEMI

## Interventions

- **DRUG:** Bempedoic Acid / Ezetimibe Oral Tablet
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05263778
- **Lead sponsor:** Kaiser Permanente
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03
- **Primary completion:** 2023-06
- **Final completion:** 2023-12
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2022-03-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05263778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05263778, "Cholesterol Lowering Via Bempedoic Acid/Ezetimibe, an ACL-Inhibiting Regimen in Acute Coronary Syndrome Study". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05263778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*